HPV16 E6 TCR T Cells for Cervical Carcinoma

Stopped Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs

Conditions

• Cervical Carcinoma

Interventions

• BIOLOGICAL: TC-E202 cells
• DRUG: IL-2
• DRUG: Fludarabine
• DRUG: Cyclophosphamide Capsules

Sponsor

TCRCure Biopharma Ltd.

Collaborators

• Fudan University